The endogenous cannabinoid (endocannabinoid) system plays an important role in fear-conditioned analgesia (FCA) and expression and extinction of conditioned fear. The hippocampus has an established role in both pain and conditioned fear and is a substrate for endocannabinoid activity. This study aimed to investigate the role of the endocannabinoid system in the ventral hippocampus (vHip) in FCA and in fear responding in the presence of nociceptive tone. Fear-conditioned rats displayed significantly increased freezing and 22-kHz ultrasonic vocalisation and a reduction in formalin-evoked nociceptive behaviour (ie, FCA) upon re-exposure to a context previously paired with footshock. Tissue levels of the endocannabinoids, anandamide, and 2-arachidonoylglycerol, as well as the fatty acid amide, palmitoylethanolamide, were significantly higher in the vHip of fear-conditioned rats compared with non-fear-conditioned controls. URB597 (inhibitor of fatty acid amide hydrolase [FAAH]), administered bilaterally into the vHip, significantly enhanced FCA during the entire trial and increased fear responding in formalin-treated rats early in the trial. The URB597-induced enhancement of FCA was blocked by intra-vHip administration of the cannabinoid 1 (CB 1 ) receptor antagonist/inverse agonist rimonabant. Intra-vHip rimonabant alone had no effect on the expression of FCA, and URB597 did not significantly alter formalin-evoked nociceptive behaviour in non-fear-conditioned rats. These data suggest an important role for the endocannabinoid system in the vHip in FCA, whereby levels of 2-arachidonoylglycerol and the FAAH substrates palmitoylethanolamide and anandamide are increased in rats expressing FCA, and pharmacological inhibition of FAAH in the vHip enhances this form of endogenous analgesia via a CB 1 receptor-dependent mechanism.
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Introduction
Fear-conditioned analgesia (FCA) is an important survival response expressed upon re-exposure to a context or cue, paired, through Pavlovian conditioning, with an aversive stimulus. Induction of FCA results in suppression of pain/nociception in both humans and rodents [9, 27] . Elucidation of substrates underpinning FCA advances our understanding of endogenous analgesic mechanisms and may aid identification of new therapeutic targets for pain-and fear-related anxiety disorders, or their comorbidity.
Aside from its function in learning and memory [50, 53] , the hippocampus has an established role in pain and aversion [ is an important structure subserving formalin-evoked nociceptive behaviour in rodents. Human neuroimaging studies have demonstrated that the hippocampus is activated by noxious stimuli [7] , and in posttraumatic stress disorder (PTSD) patients exhibiting reduced pain responding [28] . In addition, the hippocampus, particularly the ventral aspect, is anatomically connected to components of the pain neuromatrix, including the amygdala and prefrontal cortex [35, 66] . These regions are key components of the descending pain pathway [5] and facilitate the expression of FCA [9, 27, 31] . With respect to hippocampal involvement in conditioned aversion, evidence suggests that this structure mediates conditioned fear when the conditioned stimulus is contextual [43, 51] . Pharmacological inactivation or lesioning of the hippocampus impairs freezing in rats following re-exposure to contextual cues previously paired with footshock [4,6,43,
